Efepoetin Alfa
Phase 3Small molecule
Efepoetin Alfa is one of 33 small molecule programs targeting Chronic Kidney Disease. It is currently in Phase 3.
1
Indications
3
Total Trials
1
Active Trials
32
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
540 competitors in Chronic Kidney Disease
#DrugCompanyPhaseTrials
1Aranesp
AmgenPreclinical
Epogen
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Preclinical
Efepoetin Alfa
PPT Kalbe Genexine Biologics
Phase 3
Lorelco
SanofiPreclinical
Activase
RochePreclinical
Flomax
SanofiPreclinical
Genotropin
EMD SeronoPreclinical
Verquvo
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Preclinical
PROCRIT
WWim Janssens
Preclinical
Nitrostat
VViatris Specialty LLC
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Chronic Kidney Disease2 trials
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Efepoetin Alfa. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- PPT Kalbe Genexine Biologics